Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
作者： John D Brunzell , Michael Davidson , Curt D Furberg , Ronald B Goldberg , Barbara V Howard
DOI: 10.1016/J.JACC.2008.02.034
关键词: Medicine 、 Disease 、 Type 2 diabetes 、 Risk assessment 、 Insulin resistance 、 Diabetes mellitus 、 Internal medicine 、 Obesity 、 Disease cluster 、 Physical therapy 、 Risk factor
摘要: Risk factors for type 2 diabetes and cardiovascular disease (CVD) often cluster, including obesity (particularly central), insulin resistance, hyperglycemia, dyslipoproteinemia, hypertension. These conditions can also occur in isolation, they are exaggerated by physical inactivity
onlinejacc.org
elsevier.com
diabetesjournals.org 参考文章(100)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The New England Journal of Medicine. ,vol. 339, pp. 1349- 1357 ,(1998) , 10.1056/NEJM199811053391902
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The New England Journal of Medicine. ,vol. 336, pp. 153- 162 ,(1997) , 10.1056/NEJM199701163360301
Salim Yusuf, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary The Lancet. ,vol. 360, pp. 7- 22 ,(2002)
Marcel Kornitzer, Guy De Backer, A. Menotti, Giulia Ricci, Claude Hector Thilly, Michèle Dramaix Wilmet, European Collaborative trial of multifactorial prevention of coronary Heart disease: Final report on the 6-Year results. The Lancet. ,vol. 1, pp. 870- 872 ,(1986)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet. ,vol. 361, pp. 2005- 2016 ,(2003) , 10.1016/S0140-6736(03)13636-7
B Angelin, K Einarsson, K Hellström, B Leijd, Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. Journal of Lipid Research. ,vol. 19, pp. 1017- 1024 ,(1978) , 10.1016/S0022-2275(20)40685-6
Jeanine E. Roeters van Lennep, H. Tineke Westerveld, Henk W. O. Roeters van Lennep, Aelko H. Zwinderman, D. Willem Erkelens, Ernst E. van der Wall, Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 20, pp. 2408- 2413 ,(2000) , 10.1161/01.ATV.20.11.2408
S M Marcovina, J J Albers, L O Henderson, W H Hannon, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clinical Chemistry. ,vol. 40, pp. 586- 592 ,(1993) , 10.1093/CLINCHEM/39.5.773
P.J. Goadsby, R.O. Day, Y.L. Kwan, J. Miners, D.J. Birkett, 6-Mercaptopurine-related leucopenia and in vivo xanthine oxidase activity. The Lancet. ,vol. 328, pp. 869- 870 ,(1986) , 10.1016/S0140-6736(86)92911-9
Nadeem Sarwar, John Danesh, Gudny Eiriksdottir, Gunnar Sigurdsson, Nick Wareham, Sheila Bingham, S. Matthijs Boekholdt, Kay-Tee Khaw, Vilmundur Gudnason, Triglycerides and the Risk of Coronary Heart Disease 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies Circulation. ,vol. 115, pp. 450- 458 ,(2007) , 10.1161/CIRCULATIONAHA.106.637793